ENTX PE Ratio & Valuation,Is ENTX Overvalued

ENTX Relative Valuation

ENTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ENTX is overvalued; if below, it's undervalued.

Historical Valuation

Entera Bio Ltd (ENTX) is now in the Fair zone, suggesting that its current forward PS ratio of 9433.49 is considered Fairly compared with the five-year average of -4.15. The fair price of Entera Bio Ltd (ENTX) is between -- to -- according to relative valuation methord.

Relative Value

Fair Zone

-----

Current Price：2.16

Fair

-3.61

0.00

EV/EBITDA

Entera Bio Ltd. (ENTX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-2.82

EV/EBIT

Entera Bio Ltd. (ENTX) has a current EV/EBIT of -2.82. The 5-year average EV/EBIT is -2.71. The thresholds are as follows: Strongly Undervalued below -6.56, Undervalued between -6.56 and -4.64, Fairly Valued between -0.78 and -4.64, Overvalued between -0.78 and 1.14, and Strongly Overvalued above 1.14. The current Forward EV/EBIT of -2.82 falls within the Historic Trend Line -Fairly Valued range.

9433.49

Entera Bio Ltd. (ENTX) has a current PS of 9433.49. The 5-year average PS is 1052.81. The thresholds are as follows: Strongly Undervalued below -3463.63, Undervalued between -3463.63 and -1205.41, Fairly Valued between 3311.02 and -1205.41, Overvalued between 3311.02 and 5569.24, and Strongly Overvalued above 5569.24. The current Forward PS of 9433.49 falls within the Strongly Overvalued range.

0.00

P/OCF

Entera Bio Ltd. (ENTX) has a current P/OCF of 0.00. The 5-year average P/OCF is -2.00. The thresholds are as follows: Strongly Undervalued below -8.14, Undervalued between -8.14 and -5.07, Fairly Valued between 1.07 and -5.07, Overvalued between 1.07 and 4.14, and Strongly Overvalued above 4.14. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Entera Bio Ltd. (ENTX) has a current P/FCF of 0.00. The 5-year average P/FCF is -1.79. The thresholds are as follows: Strongly Undervalued below -8.45, Undervalued between -8.45 and -5.12, Fairly Valued between 1.53 and -5.12, Overvalued between 1.53 and 4.86, and Strongly Overvalued above 4.86. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Entera Bio Ltd (ENTX) has a current Price-to-Book (P/B) ratio of 6.49. Compared to its 3-year average P/B ratio of 5.75 , the current P/B ratio is approximately 12.77% higher. Relative to its 5-year average P/B ratio of 5.36, the current P/B ratio is about 21.03% higher. Entera Bio Ltd (ENTX) has a Forward Free Cash Flow (FCF) yield of approximately -7.15%. Compared to its 3-year average FCF yield of -21.11%, the current FCF yield is approximately -66.11% lower. Relative to its 5-year average FCF yield of -21.65% , the current FCF yield is about -66.95% lower.

6.49

P/B

Median3y

5.75

Median5y

5.36

-7.15

FCF Yield

Median3y

-21.11

Median5y

-21.65

Competitors Valuation Multiple

The average P/S ratio for ENTX's competitors is 1887.23, providing a benchmark for relative valuation. Entera Bio Ltd Corp (ENTX) exhibits a P/S ratio of 9433.49, which is 399.86% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of ENTX increased by 1.89% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -7.19K to -20.05K.

The secondary factor is the P/E Change, contributed -76.92%to the performance.

Overall, the performance of ENTX in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-100.00%

42.00K → 0.00

Revenue Growth

178.81%

-7.19K → -20.05K

Margin Expansion

-76.92%

-38.41 → -8.87

P/E Change

1.89%

2.12 → 2.16

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Entera Bio Ltd (ENTX) currently overvalued or undervalued?

What is Entera Bio Ltd (ENTX) fair value?

ENTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Entera Bio Ltd (ENTX) is between to according to relative valuation methord.

How does ENTX's valuation metrics compare to the industry average?

What is the current P/B ratio for Entera Bio Ltd (ENTX) as of Dec 15 2025?

As of Dec 15 2025, Entera Bio Ltd (ENTX) has a P/B ratio of 6.49. This indicates that the market values ENTX at 6.49 times its book value.

What is the current FCF Yield for Entera Bio Ltd (ENTX) as of Dec 15 2025?

As of Dec 15 2025, Entera Bio Ltd (ENTX) has a FCF Yield of -7.15%. This means that for every dollar of Entera Bio Ltd’s market capitalization, the company generates -7.15 cents in free cash flow.

What is the current Forward P/E ratio for Entera Bio Ltd (ENTX) as of Dec 15 2025?

As of Dec 15 2025, Entera Bio Ltd (ENTX) has a Forward P/E ratio of -3.61. This means the market is willing to pay $-3.61 for every dollar of Entera Bio Ltd’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Entera Bio Ltd (ENTX) as of Dec 15 2025?

As of Dec 15 2025, Entera Bio Ltd (ENTX) has a Forward P/S ratio of 9433.49. This means the market is valuing ENTX at $9433.49 for every dollar of expected revenue over the next 12 months.

ENTX Valuation

ENTX Valuation

ENTX Relative Valuation

Historical Valuation

Competitors Valuation Multiple

Performance Decomposition

People Also Watch

Frequently Asked Questions

Is Entera Bio Ltd (ENTX) currently overvalued or undervalued?

What is Entera Bio Ltd (ENTX) fair value?

How does ENTX's valuation metrics compare to the industry average?

What is the current P/B ratio for Entera Bio Ltd (ENTX) as of Dec 15 2025?

What is the current FCF Yield for Entera Bio Ltd (ENTX) as of Dec 15 2025?

What is the current Forward P/E ratio for Entera Bio Ltd (ENTX) as of Dec 15 2025?

What is the current Forward P/S ratio for Entera Bio Ltd (ENTX) as of Dec 15 2025?